

**My version of the truth ...
what happens
beyond the headline?**



Interpreting Developmental Biology's Role in Reshaping Medicine

I am a disrupter,
a skeptic,
a heretic analyst,
and a journalist!

Knowing who has "legitimate", clinical data is significant, which companies are on the "short list" to an approved treatment takes insight that can only be gained through sector experience.

DAILY DIALOGUE »

PRE-OPEN	EARLY MOVERS	MID-DAY	CLOSING BELL
<p>SEPTEMBER 27, 2013 - 1:01PM The RegMed sector goes up and down</p>			
<p>SEPTEMBER 26, 2013 - 1:03PM Rolling, not slipping</p>			
<p>SEPTEMBER 25, 2013 - 1:10PM The backward move to bend below a lower limbo pole</p>			
<p>SEPTEMBER 24, 2013 - 1:00PM What's motivating the sector, sentiment; the numbers bear out the trend</p>			

[READ MORE MID-DAY »](#)

PLATO'S CAVE

- SEPTEMBER 27, 2013 - 4:26PM
The only thing that goes up and never comes down is ... our age and experiences
- SEPTEMBER 27, 2013 - 1:01PM
The RegMed sector goes up and down
- SEPTEMBER 27, 2013 - 10:34AM
The Early Movers
- SEPTEMBER 27, 2013 - 7:34AM
Futures are DOWN, a LOWER open

WHAT'S HOT

- SEPTEMBER 26, 2013 - 9:42AM
MiMedx (MDXG) Responds to media reports
- SEPTEMBER 26, 2013 - 9:27AM
Fibrocell Science (NYSE MKT: FCSC) 11 M Offering of Common Stock

MAINLINING INVESTOR INTELLIGENCE

Labeled a disrupter, a skeptic, a heretic analyst, and an audacious journalist

Mastering the origins of conviction, one key stroke at a time

PRESS COVERAGE

Scimitar Equity's Regenerative Medicine Investors New Website Delivers Actionable Intelligence



The Who

RMi aggregates, curates and creates bottom-line content of stem and cell therapy developments to provide original analysis, vetted relevance, and high-impact synthesis.

Our offering is simple, synthesis! I analyze this sector, dissecting its claims by separating fact from science fiction.

I differentiate stem, cell therapy and regenerative medicine companies to determine who has the best probabilities of positive clinical outcomes and quantify the pricing of the event.

RMi creates value by providing facts, based on vetted information and analyzed data.

The What

Working through ambiguous and otherwise inconclusive information is the precursor of real-time intelligence. This analysis utilizes a number of collection requirements and analytic methodology to update existing views

Actionable intelligence and synthesis is the starting point, where the “eventuality” of an investment decision begins. Traditionally, this meant sifting through analyst reports and newsletters printed days, weeks, or even months in advance. Of course, by the time this information was printed the opportunities of realizing price appreciation had evaporated.

The investment community demands a consistent, relevant and timely reporting model, an evaluation of scientific platform or pipeline, with a valuation ranking to facilitate their investment decision.

RMi creates original content reviews of the cell therapy and regenerative medicine companies to not just “divine” who has the best probabilities of a clinical outcomes but “define” the probabilities and pricing of the input. RMi has evolved to adapt, address and identify investing opportunities with: e-news, actionable intelligence, data analytics and “Bottom Line” synthesis.

A barking dog or the wolf baying in the wilderness?

Henry McCusker enters his 12th year, as an analyst, journalist and digital media publisher.

I don't try to out science the scientist, co-opt the management or fifty cent the verbiage to prove I am better than those who each day perform their tasks as best they can. However, what I do is understand the short, near and long term potential of an investment opportunity.

Henry brings extensive experience in finance, capital markets, investment analysis, corporate operations and due diligence defining his unique ability for intelligence acquisition and synthesis provider.

I separate fact from science fiction by “drilling down” on a company’s statements to examine their veracity, conformity and relationship to pricing.

I endeavor to get it right! I guide investors to understand what isn't foreseeable; in other words, I tackle the infamous “unknown unknowns” problem. If you know what could be predicted, then predict it; if you can't predict ... make other plans!

The challenge

Intelligence analysis is shrouded by gaps in authenticating diagnostic information. Banking and trading influences intrude on how analysts face conflicts and reach qualitative and quantitative event judgments. Independent real-time analysis includes a transparent collection requirement and analytic methodology to update existing views.

Analysis and synthesis permits RMi to “capture” an activity or occurrence, explain its meaning to qualify its impact in the market and quantify the pricing of the event and its effect on valuation.

The biggest challenge in regenerative medicine company is stimulating investors to ... understand ... the immediacy of buy, sell and hold calls.

In this digital media age, investors and shareholders are looking at independent verification that RegMed companies are meeting milestones and reaching established goals.

Intelligence, research, analysis and synthesis

Investors crave more than “I-Bank” analyst recommendations which some times come with a “dated” opportunity cost.

Investors demand immediate access to real time intelligence and analysis forcing market “participants” to elevate RMi’s social media “anarchists” as the real-time purveyors of investment criteria with content in a “by the minute” timed news portals.

RMi doesn’t deliver traditional plain vanilla research notes that feature 'buy, hold' or 'sell' recommendations strewn with a few caveats, meaningless graphs and a cartoon.

Instead, we champion a tight and carefully vetted synthesis that identifies an event in the RegMed sector, explains its meaning, while forecasting its impact on the market, “marking” to the pricing of the event and its effect upon valuation.

Where “The Bottom Line” decision breaks out

It was a tough 2012 and a tougher 2013 for the regenerative medicine universe but, 2014 is going to be great year for clinical data! The regenerative medicine market, still at an early stage of its evolution, is likely to grow exponentially from its current base of \$1.8 B to potentially more than \$10 B by 2020.

The speed of hyper quantum market trading has accelerated and become a major problem for investors who now need metrics and actionable “avenues” of immediate communication.

Our timely synthesis keeps investors on top of the actionable intelligence that “expose” risks and opportunities not already priced into the marketplace.

RMI constantly leverages our research employing various methodologies, including fundamental, technical and qualitative approaches.

Moving the pricing needle

“NBS has a pipeline of news to validate this event ... to the future validating the reverse move! Wait ... these events take time to settle ... and then the race begins! This common practice reverse will elevate the share pricing but also actualize the peer and comparable models to reflect the PCT business opportunity, the advancing AMR-001 trial and positioning of NBS as a sector leader.” Scimitar 7/12/2013

NBS 7/12/2013: \$5.30 (post split) - NBS 9/25/2013: \$8.91 – Net: +68.11%

“Finally, a lower share volume <25 M to 15 M> and a much lower pricing. JMP was dropped for Aegis for the offering. ASTM closed at \$0.37. Expect this puppy to drop like a stone! How quickly can it be priced (?) in a dropping market and at what price? My next question is ... why put rouge on this ... blushing pig!” Scimitar Equity Research 7/25/2013

ASTM 7/25/2013: \$0.38 - ASTM 9/24/2013: \$0.28 - Net: -35.7%

Moving the pricing needle

“On one hand, if MDXG is found to be in the clear, then it could very easily recoup much of today's losses. Conversely, the confirmation of the receipt of an untitled letter solidifies the seriousness of these allegations and poses the potential to put a serious dent in MDXG's revenue growth... The questions are raised, “stuff” happens – let’s see how the rebound actualizes – never fight the FDA – adapt, evolve and settle! “ Scimitar Equity Research 9/4/2013

MDXG 9/3/2013: \$6.06 -- MDXG 9/4/2013: \$3.85 -- MDXG 9/24/2013: \$4.11 -- Net: -47.4%

“Another ‘assist’ to the BLFS team in support of Intercytex to develop improved treatments for burn injuries and recessive dystrophic epidermolysis bullosa (RDEB), an extremely debilitating skin and internal tissue disorder affecting children and adults. BLFS closed at \$0.70 with 6.3 K shares having opened at \$0.66 in its onward drive to \$1.00 by years end. Still a ... BUY.”

Scimitar Equity Research 8/25/2013

BLFS 8/25/2013: \$0.70 -- BLFS 9/25/2013: \$0.78 – Net: +11.3%

Moving the pricing needle

“All went well until PROVENGE was actually introduced to the market, which resulted in problem after problem for its parent company Dendreon. The initial hurdle that explained Dendreon’s poor performance was the problematic reimbursement situation for the \$93,000 therapy, although it later became apparent that Janssen’s competing antiandrogen agent Zytiga (abiraterone) was far more popular, and kept the lion’s share of the mCRPC market from Provenge...Three years after its FDA approval the Provenge program is still losing large amounts of money each quarter for parent company Dendreon, and threatens to burn the investors who try to buy stock on the way down - either now or later.” Scimitar Equity Research 5/14/2013

DNDN 5/24/2013: \$3.89 -- DNDN 9/25/2013: \$2.97 -- Net: -30.09%

“At least ... CMXI has REVENUE ... the capital raise will facilitate the record Q4/12 product sales, the expansion of the AutoloGel System with Medicare coverage, and the international growth of the Angel cPRP System. Dilution and structure aside – all RegMed companies need cash and their ONLY outlet is the capital markets. So hats off to Martin for the ABILITY ... to finance as I have been the negative <no apologist> one for a few past financings but, reality is upon the unappreciated RegMed sector! CMXI closed at \$0.656 on 2/19/13 with no pre-market activity and will suffer the financing announcement but, a better future should be in store. Call me crazy ... get the deal done - I still think CMXI should be trading in the \$1.00 to \$1.25 range.” Scimitar Equity Research 2/20/2013

CMXI 2/20/2013: \$0.49 -- CMXI 9/25/2013: \$.038 -- Net: -22.5%



Moving the pricing needle

Nobody wants to kick a dead horse but get the fork lift to move the R&D legacy out of the stable! Restructuring charges to be incurred will negatively affect their cash expenditures and actual results may differ materially from those originally anticipated. But, is saving R&D dollars by the retirement and switching tracks to let their telomerase inhibitor thoroughbred breakaway! GERN closed at \$1.17 and is down \$0.02 to \$1.12 on volume of only 36.1 K, so far ... expect more attrition to this event as it settles around \$1.10. SELL on news event, until it settles! Addendum ... GERN is down -\$0.07 or -5.81% to \$1.10.”

Scimitar Equity Research 2/20/2013

GERN 4/26/13: \$1.14 -- GERN 9/25/2013: \$3.12 -- Net: 274%

VSTM just "trugs" along in the preliminary stages of clinical development with twists and turns but nothing that upsets the apple cart - but great cash position! VSTM closed at \$9.68 on 5/9 DOWN from \$9.74 on 5/8 on minimal 2700 shares. The combination trial of VS-6063 plus paclitaxel for ovarian cancer is open and enrolling patients at all sites. In addition, VSTM has met with the regulatory agencies in the US and UK and are on track to initiate midyear the potentially pivotal trial of VS-6063 in mesothelioma. 2013 milestones include the following: Complete the dose finding portion of the P1/1b trial of VS-6063 plus paclitaxel in ovarian cancer; Initiate P1 clinical development of VS-4718 H1 2013 and Initiate P1 clinical development of VS-5584 H2 2013. A ...HOLD as I don't see any great expectation in a Q or 2!” Scimitar Equity Research 5/10/2013

VSTM 5/11/13: \$9.37 – VSTM 9/25/2013: \$12.86 -- Net: 27.2%



There's always a cautionary note

I don't take "infallibility pills"! Happy to say that I'm right more often than wrong, but man enough to admit when I err!

4 things that makes me nervous:

- Volatility; the RegMed sector is at times, overbought or oversold;
- It makes sense to take profits even if things are good ... or buy-in, if they aren't;
- Uncertainty reigns at many junctures and in the end, except when the markets are truly surprise by sector events;
- Most investors "reverse" fields, many investors make mistakes and more investors have no idea, but they take action anyway!

Bottom Line ... the companies that are doing well ... might be down because of a silly rotation ... those are the ones to buy!

Compliance with law, both in letter and in spirit, is the foundation of RMI's ethical standards.



Finis

My “version of the truth” is more complex than “just the facts”; it’s what happened beyond the headline and what will happen beyond to the future !

Timely insights have line extensions to a volatile pricing universe. There have been times when I have misinterpreted a “duality” of events and corrected the viewpoints in ... minutes!

My line in the sand is drawn ... separating actionable intelligence and news into short-term investment, near-term appreciation and long term achievement providing value added and insightful investment conclusions on RegMed companies meeting quarterly expectation and pricing expectation.

If you’re going to invest in stem and cell therapy and regenerative medicine companies ... start with those whose actionable intelligence fits the immediate time line versus an aged review!
The ultimate arbiter is the investor!